NASDAQ · Biotechnology

FBLG (FBLG) Stock

$0.64 +2.46% NASDAQ: FBLG Healthcare

Valuation

MetricValue
Price$0.64
Market Cap$1.35M
P/E Ratio-0.20
P/B Ratio1.21
P/S Ratio0.00
EPS (TTM)$-3.83
52-Week High$15.50
52-Week Low$0.64
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-754.75%
ROA-1.24%
ROCE-242.86%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.86
Current Ratio3.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-4.0M$-9.0M$-14.0M$-17.0M
Net Profit$-2.0M$-5.0M$-16.0M$-11.0M$-19.0M
EPS$-0.97$-3.20$-11.80$-6.80$-8.40
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$5.0M$12.0M$16.0M$10.0M
Total Liabilities$2.0M$9.0M$11.0M$14.0M$3.0M
Cash$0$2.0M$9.0M$14.0M$5.0M
Borrowings$1.0M$8.0M$2.0M$11.0M$2.0M

Latest News

FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors PR Newswire · Jul 9, 2026 FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PR Newswire · Jul 7, 2026 FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference PR Newswire · Jun 30, 2026 FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire · Jun 29, 2026 FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-4.0M$-6.0M$-12.0M$-16.0M
Investing Cash Flow$0$0$-1.0M$0$-1.0M
Financing Cash Flow$0$0$-3.0M$0$0
Net Cash Flow$0$2.0M$7.0M$5.0M$-9.0M
Free Cash Flow$-1.0M$-4.0M$-7.0M$-12.0M$-17.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-0.34
FCF Yield-838.92%
Quick Ratio1.59
Interest Coverage—
Return 1Y-93.95%
Return 3Y—
Return 5Y—

Ownership

Insiders Held10.81%
Institutions Held10.72%
Institutions Float Held12.02%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC67,6652026-03-31
Fund Evaluation Group, LLC51,7942026-03-31
Geode Capital Management, LLC29,6092026-03-31
Blackrock Inc.24,6472026-03-31
Cascade Financial Partners, LLC 16,4282026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADTX $0.01 -77.22% -0.01 $318 0.00%
AIMD $1.49 -3.87% -0.43 $10.97M 0.00%
APLMApollomics, Inc. $18.76 +2.99% -2.41 $20.69M 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
CTXR $0.57 -9.81% -0.68 $6.37M 0.00%

About FBLG

FBLG is led by CEO Peter O'Heeron, employs 13 people, headquartered in US, publicly traded since 2024.

FBLG stock trades at $0.64 with a market capitalization of $1.35M. The stock is valued at a price-to-earnings (P/E) ratio of -0.20, price-to-book of 1.21, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.64 and $15.50, and currently trades 95.9% below its 52-week high.

On profitability, FBLG generates a return on equity (ROE) of -754.75%, return on capital employed of -242.86%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides